STOCK TITAN

Erasca (NASDAQ: ERAS) raises $242.7M, funding operations into 2029

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Erasca, Inc. reported preliminary cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. The company also closed an upsized public offering of 25,875,000 common shares, including underwriters’ full overallotment exercise.

Erasca estimates net proceeds of $242.7 million from this January 2026 offering after underwriting discounts and expenses. Based on this cash position and the offering proceeds, the company estimates it has sufficient cash resources to fund operations into the first half of 2029. These figures are preliminary, unaudited and subject to completion of year-end financial procedures.

Positive

  • None.

Negative

  • None.

Insights

Large equity raise meaningfully extends Erasca’s projected cash runway.

Erasca reports preliminary cash, cash equivalents and marketable securities of $341.8 million as of December 31, 2025 and has closed an upsized equity offering of 25,875,000 shares. Net proceeds are estimated at $242.7 million, a substantial addition to its balance sheet.

Management estimates that combining this cash balance with the January 2026 offering proceeds will fund operations into the first half of 2029. For a development-stage biotech, multi-year visibility on funding can support longer clinical plans and reduce near-term financing pressure, though actual duration will depend on future spending levels.

The amounts are explicitly labeled as preliminary, unaudited and based on management estimates, and the company highlights potential differences once year-end closing and audit procedures are complete. Future SEC filings will clarify final 2025 results and any updates to its projected cash runway.

0001761918false00017619182026-01-292026-01-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

 

 

Erasca, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40602

83-1217027

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

3115 Merryfield Row

Suite 300

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (858) 465-6511

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

ERAS

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 8.01 Other Events.

On January 20, 2026, Erasca, Inc. (the “Company”) disclosed that its cash, cash equivalents and marketable securities for the Company as of December 31, 2025 was approximately $341.8 million. On January 23, 2026, the Company announced that it closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares (the “January 2026 Offering”). The estimated net proceeds to the Company from the January 2026 Offering, after deducting the underwriting discounts and commissions and other offering expenses, is $242.7 million.

The cash, cash equivalents and marketable securities and the net proceeds information above are based on preliminary unaudited information and management estimates. The cash, cash equivalents and marketable securities information is not a comprehensive statement of the Company’s financial results as of and for the fiscal year ended December 31, 2025 and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, these preliminary estimates.

The Company estimates that, based on its cash, cash equivalents and marketable securities as of December 31, 2025 and the net proceeds from the January 2026 Offering, it has sufficient cash resources to fund the Company’s operations into the first half of 2029.

Forward-Looking Statements

The Company cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on the Company’s current beliefs and expectations and include, but are not limited to: statements regarding the preliminary estimate of the Company’s cash, cash equivalents and marketable securities as of December 31, 2025; the Company’s estimated net proceeds from the January 2026 Offering; and the Company’s belief that based on its cash, cash equivalents and marketable securities at December 31, 2025, and the net proceeds from the January 2026 Offering, it has sufficient cash resources to fund the Company’s operations into the first half of 2029. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the Company’s actual results for the fourth quarter or full year of 2025 may differ materially from our preliminary estimates as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting or other quarter-end and year-end procedures; the Company’s estimates regarding the net proceeds from the January 2026 Offering may change; the Company may use its capital resources sooner than expected; and other risks described in the Company’s prior filings with the SEC, including under the heading “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Erasca, Inc.

 

 

 

 

Date:

January 29, 2026

By:

/s/ Ebun Garner

 

 

 

General Counsel

 


FAQ

What cash balance did Erasca (ERAS) report as of December 31, 2025?

Erasca reported preliminary cash, cash equivalents and marketable securities of approximately $341.8 million as of December 31, 2025. This figure is based on unaudited information and management estimates and will be finalized after completion of year-end financial closing procedures and related reviews.

How much did Erasca (ERAS) raise in its January 2026 public offering?

Erasca closed an upsized public offering of 25,875,000 common shares in January 2026. The company estimates net proceeds of about $242.7 million after underwriting discounts, commissions and offering expenses, including shares sold through the underwriters’ full exercise of their option.

How long does Erasca expect its cash to fund operations after the offering?

Erasca estimates that its cash, cash equivalents and marketable securities at December 31, 2025, together with the January 2026 offering proceeds, will fund operations into the first half of 2029. This projection is forward-looking and subject to business risks and actual spending levels.

Are Erasca’s reported cash and proceeds figures audited?

No. Erasca states that its cash, cash equivalents, marketable securities and net proceeds figures are preliminary and unaudited, based on management estimates. The company notes that its independent registered public accounting firm has not audited or reviewed these estimates or provided any assurance on them.

What risks could cause Erasca’s preliminary 2025 estimates to change?

Erasca notes that actual fourth-quarter and full-year 2025 results may differ from preliminary estimates due to changes in assumptions, completion of internal control reviews and other year-end procedures. It also cites potential changes in estimated net proceeds and the possibility of using capital resources sooner than expected.

What type of forward-looking statements did Erasca include in this 8-K?

Erasca’s forward-looking statements cover its preliminary cash estimate, its estimated net proceeds from the January 2026 offering, and its belief that these resources can fund operations into early 2029. The company cautions that actual outcomes may differ due to business risks and previously disclosed risk factors.
Erasca, Inc.

NASDAQ:ERAS

ERAS Rankings

ERAS Latest News

ERAS Latest SEC Filings

ERAS Stock Data

3.19B
227.86M
11.68%
81.93%
6.6%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO